Jazz Pharmaceuticals plc
JAZZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | -0.07 | 1.27 | 0.10 |
| FCF Yield | 17.70% | 13.72% | 7.77% | 9.64% |
| EV / EBITDA | 7.47 | 8.33 | 10.14 | 12.81 |
| Quality | ||||
| ROIC | 7.77% | 7.76% | -0.39% | 4.29% |
| Gross Margin | 89.05% | 88.64% | 85.23% | 85.76% |
| Cash Conversion Ratio | 2.49 | 2.63 | -5.68 | -2.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.60% | 7.41% | 15.69% | 12.70% |
| Free Cash Flow Growth | 26.20% | 38.03% | 5.57% | 40.85% |
| Safety | ||||
| Net Debt / EBITDA | 2.46 | 2.96 | 3.36 | 5.41 |
| Interest Coverage | 3.01 | 2.00 | -0.23 | 0.61 |
| Efficiency | ||||
| Inventory Turnover | 0.93 | 0.73 | 0.76 | 0.41 |
| Cash Conversion Cycle | 393.97 | 481.39 | 485.89 | 871.73 |